Citius Oncology, Inc (CTOR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Citius Oncology, Inc (CTOR) is down 40.8% since the beginning of the year. At $1 per share, CTOR is trading 73.7% below its 52-week high of $2.

Citius Oncology, Inc (CTOR) has returned -40.77% so far this year and -71.25% over the past 12 months.

Based on dividend-adjusted daily data since Dec 8, 2022, CTOR's average daily return is +0.12%, while the average monthly return is +2.36%. At this rate, an investment would double in approximately 2.5 years.

Historically, 57% of months were positive and 43% were negative. The best month was Jun 2025 with a return of +383.3%, while the worst month was Aug 2024 at -83.6%. The longest winning streak lasted 18 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CTOR closed higher 35% of trading days. The best single day was Aug 5, 2024 with a return of +192.9%, while the worst single day was Aug 13, 2024 at -92.1%.

Citius Oncology, Inc has an annualized alpha of 38.20%, beta of -0.10, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 08, 2022.

• This stock participated in 261.92% of S&P 500 Index downside but only -85.72% of its upside - more exposed to losses than it benefited from rallies.
• Beta of -0.10 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CTOR ranks 6 for risk / return — above 6% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Citius Oncology, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Citius Oncology, Inc was 98.78%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Citius Oncology, Inc drawdown is 98.54%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Citius Oncology, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Citius Oncology, Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.